Source: Annual Congress 2013 –COPD drugs: new findings
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Rodriguez-Roisin, L. Fabbri, C. Orevillo, C. Fernandez, P. Darken, E. St. Rose, T. Fischer, C. Kollar, C. Reisner (Barcelona, Spain; Modena, Italy; Redwood City, Little Falls, United States Of America). Integrated analyses of phase II safety data support the safety of glycopyrrolate-formoterol fumarate (GFF) MDI (PT003) and glycopyrrolate (GP) MDI (PT001) in COPD. Eur Respir J 2013; 42: Suppl. 57, 4141

Member's Comments

No comment yet.

Related content which might interest you: Pooled analyses of five phase 2b studies support dose selection of glycopyrrolate-formoterol (GFF) MDI (PT003) 18/9.6 μg for phase III development Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Pooled analyses of QTcF across six phase 2b studies with glycopyrrolate-formoterol fumarate (GFF) MDI (PT003), its components and active comparators Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Beneficial effect of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) fixed-dose combination, delivered using a novel MDI co-suspension technology (GFF MDI), in COPD GOLD group A and B patients Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Pooled analysis of 24-h lung function following treatment with the LAMA/LABA glycopyrronium/formoterol fumarate fixed-dose combination, delivered by a novel MDI co-suspension technology (GFF MDI), in COPD patients (pts) Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Benefits of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) MDI FDC, delivered using a novel MDI co-suspension technology (GFF MDI), increase with baseline symptom severity in COPD patients (pts) Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 LATE-BREAKING ABSTRACT: TRILOGY: a phase III study to evaluate the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) in COPD patients Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Glycopyrronium (GLY) and tiotropium (TIO) comparison: Lung function, dyspnea and health status in COPD patients in all GOLD groups Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three phase III studies Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Benefit of FDC budesonide (BUD) and formoterol fumarate (FF) FDC delivered by a novel MDI co-suspension technology (BFF MDI), in patients (pts) with moderate-to-severe COPD Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Safety, pharmacodynamics (PD) and pharmacokinetics (PK) of darotropium (DARO) and vilanterol (VI) in healthy subjects: Two phase 1 studies Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 LATE-BREAKING ABSTRACT: TRINITY: A phase III study to compare the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) with tiotropium (Tio) and a free triple combination of BDP/FF (Foster®) + Tio in COPD patients Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 Inhalation characteristics with Spiromax® (S) versus Turbuhaler® (T) dry powder inhalers (DPI) in healthy adults (HA) and in patients with asthma (A) or COPD Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 Onset of action of aclidinium (ACL), glycopyrronium (GLY) and tiotropium (TIO): A comparison in COPD patients Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 LATE-BREAKING ABSTRACT: Pulmonary deposition of a novel LAMA/LABA Co-Suspension[sup][trade][/sup] technology glycopyrronium/formoterol (GFF) MDI in healthy subjects (PT003020) Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016 Enhanced training on how to use a dry powder inhaler (DPI) improves the inhalation manoeuvre (IM) of patients with asthma (child 6–17 yrs and adult >17 yrs) or COPD and in healthy adults (HA) when they use a Spiromax® (S) and Turbuhaler® (T) DPI Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy in healthy subjects Source: International Congress 2014 – Asthma and COPD management Year: 2014 Safety profile of glycopyrronium in patients with COPD: An innovative approach to analyse data from post-marketing surveillance (PMS) Source: International Congress 2014 – Asthma and COPD management Year: 2014 LATE-BREAKING ABSTRACT: A Phase 1b study of PUR0200, a novel tiotropium formulation, in COPD patients Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014